Re: The Role Of PGNX in RUM

[Guest guest]

-Dr.Kiran

Your message is great.

My only concern is how to get this message across to Doctors,Retail

Chemists and patients.

Shall we be chained to a discussion group in internet like 000

others.

Regards

bhava

pharmedtradenews@...

-- In netrum , kiran chaudhari <kiranchaudhari7@...>

wrote:

>

> Dear netrumians,

>

> We were at " RATIONAL USE OF MEDICINE "

>

> IT is the

>

> " RIGHT MEDICINE

>

> AT

>

> RIGHT TIME

>

> IN

>

> RIGHT DOSE

>

> FOR

>

> RIGHT DURATION

>

> BY

>

> RIGHT ROUTE OF ADMINISTRATION

>

> FOR

>

> RIGHT DIAGNOSIS

>

> FOR

>

> THE RIGHT PERSON!!!!!!!!!!!! "

>

> The right person in the above definition compels us to think

about the individual variations that exists among us i.e.

individuals.

>

> This is the point of concentration to minimize the ADRs,

Maximize the efficacy and optimize the therapy.

>

> And the tool to tackle this is " Pharmacogenomics " .

>

> Before going in the area of PGNX I would like to first revise

another well known term in the next step of discussion the concept

of `P' drug rather we shall call it " P " Medicine.

>

> Can any one please explain this concept for better understanding?

>

> Regards,

> Dr Kiran Chaudhari

> Lecturer, Pharmacology,

> GMC, Nagpur

>

>

> ---------------------------------

> Why delete messages? Unlimited storage is just a click away.

>

[Guest guest]

Hi, A practising doctor has his list of drugs for most of the diseases which he diagnoses and commonly prescribes. With his experience, he knows about their efficacy, safety and affordability. These are p-drugs or 'personal drugs' Anupama.kiran chaudhari <kiranchaudhari7@...> wrote: Dear netrumians, We were at “RATIONAL USE OF MEDICINE” IT is the “RIGHT MEDICINE AT RIGHT TIME IN RIGHT DOSE FOR RIGHT DURATION BY RIGHT ROUTE OF ADMINISTRATION FOR RIGHT DIAGNOSIS FOR THE RIGHT PERSON!!!!!!!!!!!!” The right person in the above definition compels us to think about the individual variations that exists among us i.e. individuals. This is the point of concentration to minimize the ADRs, Maximize the efficacy and optimize the therapy. And the tool to tackle this is “Pharmacogenomics”. Before going in the area of PGNX I would like to first revise another well known term in the next step of discussion the concept of ‘P’ drug rather we shall call it “P” Medicine. Can any one please explain this concept for better understanding? Regards, Dr Kiran Chaudhari Lecturer, Pharmacology, GMC, Nagpur Why delete messages? Unlimited storage is just a click away.

Why delete messages? Unlimited storage is just a click away.

[Guest guest]

Dear friends,Pharmacogenomics has a lot of potential in clinical practice. This field of pharmacology is being used as a guidance for rational use of medicines in European nations currently. The most surprising news is that, this usage of pharmacogenetic testing for routine patient care is not a new endeavor, but it has been done for almost the last 8 years in such nations. The major limiting factor in our country is lack of adequate resources to set up enough labs all over the country. It would also raise a question of affordability by the patients for pharmacogenetic testing. This concern has been validated with the reduction in total health care expenses that the patient has to face in event of therapeutic failures or

adverse drug reactions. There are enough agencies to fund research projects on genomics, which are remaining unutilized. These depot of resources like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various institutions all over the country and set up pharmacogenetic labs with personnel. This has a long way to go, with the current rate of progress in research. Dr.SurendiranJIPMER

Chat on a cool, new interface. No download required. Click here.

[Guest guest]



Rightly pointed out by Dr. Suren. We all know that the role of PGNX in RUM would greatly enhance our approach to unanticipated drug toxicity and would narrow the risk/benefit margin of drug therapy. Such an integrative strategy is a key element directed towards the promotion of optimal drug therapy. The concept of PGNX is not only a rational (RUM) but also profitable during drug discovery process (can earn 5 billion USD/year). The risk like 1 out of 10 pass clinical trials to market and 1 out of 20 recover development costs may maximally be minimized.

Researches in this direction are being done in many places of clinical pharmacology. I know few scientists who are involved directly in this field such as Dr. Gaidgek (of USA who first time worked in gene deletion that explains slow metabolism), Professor Leif Bertilsson (of Clinical Pharmacology Dept, Karolinska Inst, Huddinge University Hospital, Sweden), Dr. Collen Masimirembwa (He has now started his own lab in Nairobi, Kenya. Earlier he was in AstraZeneca), Professor Olavi Pelkonen (of Dept of Pharmacology and Toxicology, University of Oulu).

With the passage of time, we may take the advantage of this novel drug targeted PGNX; if not now, then our successors will definitely devour its fruits. PGNX as a part of RUM will improve human health. It will be helpful in both infectious diseases and noninfectious diseases, microbial drug resistance, where there is treatment failure, and in non-responders (30-60% of patients do not respond to treatment by available drugs). It will also help in drug intellectual property.

S. Ziaur Rahman, Aligarh

Re: "The Role Of PGNX in RUM"

Dear friends,Pharmacogenomics has a lot of potential in clinical practice. This field of pharmacology is being used as a guidance for rational use of medicines in European nations currently. The most surprising news is that, this usage of pharmacogenetic testing for routine patient care is not a new endeavor, but it has been done for almost the last 8 years in such nations. The major limiting factor in our country is lack of adequate resources to set up enough labs all over the country. It would also raise a question of affordability by the patients for pharmacogenetic testing. This concern has been validated with the reduction in total health care expenses that the patient has to face in event of therapeutic failures or adverse drug reactions. There are enough agencies to fund research projects on genomics, which are remaining unutilized. These depot of resources like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various institutions all over the country and set up pharmacogenetic labs with personnel. This has a long way to go, with the current rate of progress in research. Dr.SurendiranJIPMER

Chat on a cool, new interface. No download required. Click here.

[Guest guest]

Hello all,

Although this article is not related with pharmacogenomics, it could be helpful to understand the concept of P-drug.

Parmar DM, Jadav SP. The concept of personal drugs in the undergraduate pharmacology practical curriculum. Indian J Pharmacol 2007;39:165-7DR.SHILPA JADAVASSISTANT PROFESSORDEPARTMENT OF PHARMACOLOGYM.P.SHAH MEDICAL COLLEGEJAMNAGAR,GUJARATINDIA

Dear netrumians,

We were at “RATIONAL USE OF MEDICINEâ€

IT is the

“RIGHT MEDICINE

AT

RIGHT TIME

IN

RIGHT DOSE

FOR

RIGHT DURATION

BY

RIGHT ROUTE OF ADMINISTRATION

FOR

RIGHT DIAGNOSIS

FOR

THE RIGHT PERSON!!!!!! !!!!!!â€

The right person in the above definition compels us to think about the individual variations that exists among us i.e. individuals.

This is the point of concentration to minimize the ADRs, Maximize the efficacy and optimize the therapy.

And the tool to tackle this is “Pharmacogenomicsâ€.

Before going in the area of PGNX I would like to first revise another well known term in the next step of discussion the concept of ‘P’ drug rather we shall call it “P†Medicine.

Can any one please explain this concept for better understanding?

Regards,

Dr Kiran Chaudhari

Lecturer, Pharmacology,

GMC, Nagpur

Why delete messages? Unlimited storage is just a click away.

Why delete messages? Unlimited storage is just a click away.

Forgot the famous last words? Access your message archive online. Click here.

[Guest guest]

Dear Dr. S. Ziaur Rahman and Dr Suren, Giving the very much clear idea about “p drug” is really appreciable. Dr Suren, being a student from JIPMER, (where the very first Pharmacogenomics laboratory has been

established) can you through some light on the history of Pharmacogenomics? Regards, Dr Kiran Chaudhari Lecturer, Pharmacology, GMC, Nagpuribnsinaacademy <ibnsinaacademy@...> wrote:  Rightly pointed out by Dr. Suren. We all know that

the role of PGNX in RUM would greatly enhance our approach to unanticipated drug toxicity and would narrow the risk/benefit margin of drug therapy. Such an integrative strategy is a key element directed towards the promotion of optimal drug therapy. The concept of PGNX is not only a rational (RUM) but also profitable during drug discovery process (can earn 5 billion USD/year). The risk like 1 out of 10 pass clinical trials to market and 1 out of 20 recover development costs may maximally be minimized. Researches in this direction are being done in many places of clinical pharmacology. I know few scientists who are involved directly in this field such as Dr. Gaidgek (of USA who first time worked in gene deletion that explains slow

metabolism), Professor Leif Bertilsson (of Clinical Pharmacology Dept, Karolinska Inst, Huddinge University Hospital, Sweden), Dr. Collen Masimirembwa (He has now started his own lab in Nairobi, Kenya. Earlier he was in AstraZeneca), Professor Olavi Pelkonen (of Dept of Pharmacology and Toxicology, University of Oulu). With the passage of time, we may take the advantage of this novel drug targeted PGNX; if not now, then our successors will definitely devour its fruits. PGNX as a part of RUM will improve human health. It will be helpful in both infectious diseases and noninfectious diseases, microbial drug resistance, where there is treatment failure, and in non-responders (30-60% of patients do not respond to treatment by available drugs). It will also help in drug

intellectual property. S. Ziaur Rahman, Aligarh Re: "The Role Of PGNX in RUM" Dear friends,Pharmacogenomics has a lot of potential in clinical practice. This field of pharmacology is being used as a guidance for rational use of medicines in European nations currently. The most surprising news is that, this usage of pharmacogenetic testing for routine patient care is not a new endeavor, but it has been done for almost the last 8 years in such nations. The major limiting factor in our country is lack of adequate resources to set up enough labs all over the country. It would also raise a question of affordability by

the patients for pharmacogenetic testing. This concern has been validated with the reduction in total health care expenses that the patient has to face in event of therapeutic failures or adverse drug reactions. There are enough agencies to fund research projects on genomics, which are remaining unutilized. These depot of resources like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various institutions all over the country and set up pharmacogenetic labs with personnel. This has a long way to go, with the current rate of progress in research. Dr.SurendiranJIPMER Chat on a cool, new interface. No download required. Click here.

5, 50, 500, 5000 - Store N number of mails in your inbox. Click here.

[Guest guest]

Dear Dr. S. Ziaur Rahman and Dr Suren, Giving the very much clear idea about “p drug” is really appreciable. Dr Suren, being a student from JIPMER, (where the very first Pharmacogenomics laboratory has been

established) can you throw some light on the history of Pharmacogenomics? Regards, Dr Kiran Chaudhari Lecturer, Pharmacology, GMC, Nagpuribnsinaacademy <ibnsinaacademy@...> wrote:  Rightly pointed out by Dr. Suren. We all know that

the role of PGNX in RUM would greatly enhance our approach to unanticipated drug toxicity and would narrow the risk/benefit margin of drug therapy. Such an integrative strategy is a key element directed towards the promotion of optimal drug therapy. The concept of PGNX is not only a rational (RUM) but also profitable during drug discovery process (can earn 5 billion USD/year). The risk like 1 out of 10 pass clinical trials to market and 1 out of 20 recover development costs may maximally be minimized. Researches in this direction are being done in many places of clinical pharmacology. I know few scientists who are involved directly in this field such as Dr. Gaidgek (of USA who first time worked in gene deletion that explains slow

metabolism), Professor Leif Bertilsson (of Clinical Pharmacology Dept, Karolinska Inst, Huddinge University Hospital, Sweden), Dr. Collen Masimirembwa (He has now started his own lab in Nairobi, Kenya. Earlier he was in AstraZeneca), Professor Olavi Pelkonen (of Dept of Pharmacology and Toxicology, University of Oulu). With the passage of time, we may take the advantage of this novel drug targeted PGNX; if not now, then our successors will definitely devour its fruits. PGNX as a part of RUM will improve human health. It will be helpful in both infectious diseases and noninfectious diseases, microbial drug resistance, where there is treatment failure, and in non-responders (30-60% of patients do not respond to treatment by available drugs). It will also help in drug

intellectual property. S. Ziaur Rahman, Aligarh Re: "The Role Of PGNX in RUM" Dear friends,Pharmacogenomics has a lot of potential in clinical practice. This field of pharmacology is being used as a guidance for rational use of medicines in European nations currently. The most surprising news is that, this usage of pharmacogenetic testing for routine patient care is not a new endeavor, but it has been done for almost the last 8 years in such nations. The major limiting factor in our country is lack of adequate resources to set up enough labs all over the country. It would also raise a question of affordability by

the patients for pharmacogenetic testing. This concern has been validated with the reduction in total health care expenses that the patient has to face in event of therapeutic failures or adverse drug reactions. There are enough agencies to fund research projects on genomics, which are remaining unutilized. These depot of resources like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various institutions all over the country and set up pharmacogenetic labs with personnel. This has a long way to go, with the current rate of progress in research. Dr.SurendiranJIPMER Chat on a cool, new interface. No download required. Click here.

Now you can chat without downloading messenger. Click here to know how.

[Guest guest]

Dear Dr. Kiran Chaudhri

Before Dr. Suren may tell the first lab of pharmacogenomic in India and abroad. Here is a brief history related to the concept of PGNX:

In the early 1950s, two interesting findings – prolonged muscle relaxation after curarization with suxamethonium in patients with congenital cholinesterase deficiency and acute hemolysis induced by antimalarial drugs (like primaquine) in patients with low G-6 PD activity set the stage for new developments. By the end of 1980s and 1990s, the causal genes coding for debrisoquine hydroxylase, or CYP2D6 had been cloned and characterized, inaugurating a new field of Pharmacogenetics and Pharmacogenomic (1-3).

References:

1. Tribut O, Lessard Y, Reyman JM, Allain H, Bentue-Ferrer D. Pharmacogenomics. Med Sci Moni 2002: 8(7): 52-163

2. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in black African population: Association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42:713-9.

3. Syed Ziaur Rahman, Anil Kumar, KC Singhal. Pharmacogenetic and Pharmacogenomic in the sphere of Pharmacovigilance – A Review. In Current Trends in Paediatrics, Vol. 1. 2005. Ed. GP Mathur and Sarla Mathur. Academa Publishers, New Delhi, pp20-32.

S. Ziaur Rahman, Aligarh

Re: "The Role Of PGNX in RUM"

Dear friends,Pharmacogenomics has a lot of potential in clinical practice. This field of pharmacology is being used as a guidance for rational use of medicines in European nations currently. The most surprising news is that, this usage of pharmacogenetic testing for routine patient care is not a new endeavor, but it has been done for almost the last 8 years in such nations. The major limiting factor in our country is lack of adequate resources to set up enough labs all over the country. It would also raise a question of affordability by the patients for pharmacogenetic testing. This concern has been validated with the reduction in total health care expenses that the patient has to face in event of therapeutic failures or adverse drug reactions. There are enough agencies to fund research projects on genomics, which are remaining unutilized. These depot of resources like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various institutions all over the country and set up pharmacogenetic labs with personnel. This has a long way to go, with the current rate of progress in research. Dr.SurendiranJIPMER

Chat on a cool, new interface. No download required. Click here.

5, 50, 500, 5000 - Store N number of mails in your inbox. Click here.

[Guest guest]

Dear Dr S. Ziaur Rahman Can you also provide some details about difference between Pharmacogenetics and pharmacogenomics? which one will be helpful towards personalized medicine concept? regards, Kiran ibnsinaacademy <ibnsinaacademy@...> wrote: Dear Dr. Kiran Chaudhri Before Dr. Suren may tell the first lab of pharmacogenomic in India and abroad. Here is a brief history related to the concept of PGNX: In the early 1950s, two interesting findings – prolonged muscle relaxation after curarization with suxamethonium in patients with congenital cholinesterase deficiency and acute hemolysis induced by antimalarial drugs (like primaquine) in patients with low G-6 PD activity set the stage for new developments. By the end of 1980s and 1990s, the causal genes coding for debrisoquine hydroxylase, or CYP2D6 had been cloned and characterized, inaugurating a new field of Pharmacogenetics and Pharmacogenomic (1-3). References: 1. Tribut O, Lessard Y, Reyman JM, Allain H, Bentue-Ferrer D. Pharmacogenomics. Med Sci Moni 2002: 8(7): 52-163 2. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in black African population: Association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42:713-9. 3. Syed Ziaur Rahman, Anil Kumar, KC Singhal. Pharmacogenetic and Pharmacogenomic in the

sphere of Pharmacovigilance – A Review. In Current Trends in Paediatrics, Vol. 1. 2005. Ed. GP Mathur and Sarla Mathur. Academa Publishers, New Delhi, pp20-32. S. Ziaur Rahman, Aligarh Re: "The Role Of PGNX in RUM" Dear friends,Pharmacogenomics has a lot

of potential in clinical practice. This field of pharmacology is being used as a guidance for rational use of medicines in European nations currently. The most surprising news is that, this usage of pharmacogenetic testing for routine patient care is not a new endeavor, but it has been done for almost the last 8 years in such nations. The major limiting factor in our country is lack of adequate resources to set up enough labs all over the country. It would also raise a question of affordability by the patients for pharmacogenetic testing. This concern has been validated with the reduction in total health care expenses that the patient has to face in event of therapeutic failures or adverse drug reactions. There are enough agencies to fund research projects on genomics, which are remaining unutilized. These depot of resources like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various institutions all over the country and set up pharmacogenetic labs with personnel. This

has a long way to go, with the current rate of progress in research. Dr.SurendiranJIPMER Chat on a cool, new interface. No download required. Click here. 5, 50, 500, 5000 - Store N number of mails in your inbox. Click here.

Why delete messages? Unlimited storage is just a click away.

[Guest guest]

Dear Dr.KiranI can tell as much as i can. Let me put it in this way.. when a drug is administered, it produces varied responses in different individuals. When the study involves identification of the genetic basis of this variation, it is called as pharmacogenetics. For eg. In case of the drug phenytoin - the genetic polymorphisms in CYP2C9 namely *2 and *3 alleles cause variation in drug response. When a study is focused on these polymorphisms alone, it is called as pharmacogenetics. But in a similar case, if a study of the ENTIRE genome is done so as to find out all the multigenic determinants of the varied drug response, it is called as pharmacogenomics.Dr.Surendiran Re: "The Role Of PGNX in RUM" Dear friends,Pharmacogenomics has a lot

of potential in clinical practice. This field of pharmacology is being used as a guidance for rational use of medicines in European nations currently. The most surprising news is that, this usage of pharmacogenetic testing for routine patient care is not a new endeavor, but it has been done for almost the last 8 years in such nations. The major limiting factor in our country is lack of adequate resources to set up enough labs all over the country. It would also raise a question of affordability by the patients for pharmacogenetic testing. This concern has been validated with the reduction in total health care expenses that the patient has to face in event of therapeutic failures or adverse drug reactions. There are enough agencies to fund research projects on genomics, which are remaining unutilized. These depot of resources like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various institutions all over the country and set up pharmacogenetic labs

with personnel. This

has a long way to go, with the current rate of progress in research. Dr.SurendiranJIPMER Chat on a cool, new interface. No download required. Click here. 5, 50, 500, 5000 - Store N number of mails in your inbox. Click here. Why delete messages? Unlimited storage is just a click away.

Save all your chat conversations. Find them online.

[Guest guest]

Dear Dr.Kiran,Regarding the history of pharmacogenomics - The chapter of Pharmacogenetics in 11th edition of Goodman Gilman is very good and provides the scope of pharmacogenetics in clinical use as well as in drug development and in clinical trials. I would suggest you go through that chapter, as i myself got enlightened a lot from it and am very much impressed.RegardsDr.Surendiran Re: "The Role Of PGNX in RUM" Dear friends,Pharmacogenomics has a lot of potential in clinical practice. This field of pharmacology is being used as a guidance for rational use of medicines in European nations currently. The most surprising

news is that, this usage of pharmacogenetic testing for routine patient care is not a new endeavor, but it has been done for almost the last 8 years in such nations. The major limiting factor in our country is lack of adequate resources to set up enough labs all over the country. It would also raise a question of affordability by

the patients for pharmacogenetic testing. This concern has been validated with the reduction in total health care expenses that the patient has to face in event of therapeutic failures or adverse drug reactions. There are enough agencies to fund research projects on genomics, which are remaining unutilized. These depot of resources like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various institutions all over the country and set up pharmacogenetic labs with personnel. This has a long way to go, with the current rate of progress in research. Dr.SurendiranJIPMER Chat on a cool, new interface. No download required. Click here. 5, 50, 500, 5000 - Store N number of mails in your inbox.. Click here.

Save all your chat conversations. Find them online.

[Guest guest]

The terms pharmacogenomics and pharmacogenetics tend to be used interchangeably, and a precise, consensus definition of either remains elusive. Pharmacogenetics is generally regarded as the study of genetic variation that gives rise to differing response to drugs, while pharmacogenomics is the broader application of genomic technologies to new drug discovery and further characterization of older drugs. Pharmacogenetics considers one or at most a few genes of interest, while pharmacogenomics considers the entire genome. Much of current clinical interest is at the level of pharmacogenetics, involving variation in genes involved in drug metabolism with a particular emphasis on improving drug safety.

S. Ziaur Rahman, Aligarh

Re: "The Role Of PGNX in RUM"

Dear friends,Pharmacogenomics has a lot of potential in clinical practice. This field of pharmacology is being used as a guidance for rational use of medicines in European nations currently. The most surprising news is that, this usage of pharmacogenetic testing for routine patient care is not a new endeavor, but it has been done for almost the last 8 years in such nations. The major limiting factor in our country is lack of adequate resources to set up enough labs all over the country. It would also raise a question of affordability by the patients for pharmacogenetic testing. This concern has been validated with the reduction in total health care expenses that the patient has to face in event of therapeutic failures or adverse drug reactions. There are enough agencies to fund research projects on genomics, which are remaining unutilized. These depot of resources like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various institutions all over the country and set up pharmacogenetic labs with personnel. This has a long way to go, with the current rate of progress in research. Dr.SurendiranJIPMER

Chat on a cool, new interface. No download required. Click here.

5, 50, 500, 5000 - Store N number of mails in your inbox. Click here.

Why delete messages? Unlimited storage is just a click away.

[Guest guest]

To be so concise and brief on this subject, In fact pharmacogenomics is a bough of pharmacogenetics and pharmacogenomics is a biomedical science that plans to employ this knowledge to modify medicine therapies according the patients’ individual genetic structure. Medical Practitioners anticipate using Pharmacogenomics to expand safer and additional effective medical treatments. Pharmacogenetics, a science that deals with the heritable traits accountable for the individual disparities in the ways people react to medcines thank you ibnsinaacademy <ibnsinaacademy@...> wrote: The terms pharmacogenomics and pharmacogenetics tend to be used interchangeably, and a precise, consensus definition of either remains elusive. Pharmacogenetics is generally regarded as the study of genetic variation that gives rise to differing response to drugs, while pharmacogenomics is the broader application of genomic technologies to new drug discovery and further characterization of older drugs. Pharmacogenetics considers one or at most a few genes of interest, while pharmacogenomics considers the entire genome. Much of

current clinical interest is at the level of pharmacogenetics, involving variation in genes involved in drug metabolism with a particular emphasis on improving drug safety. S. Ziaur Rahman, Aligarh Re: "The Role Of PGNX in RUM" Dear friends,Pharmacogenomics has a lot of potential in clinical practice. This field of pharmacology is being used as a guidance for rational use of medicines in European nations currently. The most surprising news is that, this usage of pharmacogenetic testing for routine patient care is not a new endeavor, but it

has been done for almost the last 8 years in such nations. The major limiting factor in our country is lack of adequate resources to set up enough labs all over the country. It would also raise a question of affordability by the patients for pharmacogenetic testing. This concern has been validated with the reduction in total health care expenses that the patient has to face in event of therapeutic failures or adverse drug reactions. There are enough agencies to fund research projects on genomics, which are remaining unutilized. These depot of resources like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various institutions all over the country and set up pharmacogenetic labs with personnel. This has a long way to go, with the current rate of progress in research. Dr.SurendiranJIPMER Chat on a cool, new interface. No download required. Click here. 5, 50, 500, 5000 - Store N number of mails in your inbox. Click here. Why delete messages? Unlimited storage is just a click away.

Never miss a thing. Make your homepage.

[Guest guest]

Hi,

NetRUM is meant to share the information /knowledge with members for

capacity building. Please do not guide members to read from some

book. It will be a better service that one reads, copies the

relevant information and pastes the same on NetRUM with full

reference.

Dr Vijay Thawani

Groupie



Rightly pointed out by Dr. Suren. We all know that

> the role of PGNX in RUM would greatly enhance our approach to

unanticipated drug toxicity and would narrow the risk/benefit margin

of drug therapy. Such an integrative strategy is a key element

directed towards the promotion of optimal drug therapy. The concept

of PGNX is not only a rational (RUM) but also profitable during drug

discovery process (can earn 5 billion USD/year). The risk like 1 out

of 10 pass clinical trials to market and 1 out of 20 recover

development costs may maximally be minimized.

>

> Researches in this direction are being done in many places of

clinical pharmacology. I know few scientists who are involved

directly in this field such as Dr. Gaidgek (of USA who first

time worked in gene deletion that explains slow

> metabolism), Professor Leif Bertilsson (of Clinical Pharmacology

Dept, Karolinska Inst, Huddinge University Hospital, Sweden), Dr.

Collen Masimirembwa (He has now started his own lab in Nairobi,

Kenya. Earlier he was in AstraZeneca) , Professor Olavi Pelkonen (of

Dept of Pharmacology and Toxicology, University of Oulu).

>

> With the passage of time, we may take the advantage of this

novel drug targeted PGNX; if not now, then our successors will

definitely devour its fruits. PGNX as a part of RUM will improve

human health. It will be helpful in both infectious diseases and

noninfectious diseases, microbial drug resistance, where there is

treatment failure, and in non-responders (30-60% of patients do not

respond to treatment by available drugs). It will also help in drug

> intellectual property.

>

> S. Ziaur Rahman, Aligarh

>

>

>

>

> Re: " The Role Of PGNX in RUM "

>

>

>

> Dear friends,

>

> Pharmacogenomics has a lot of potential in clinical practice. This

field of pharmacology is being used as a guidance for rational use

of medicines in European nations currently. The most surprising news

is that, this usage of pharmacogenetic testing for routine patient

care is not a new endeavor, but it has been done for almost the last

8 years in such nations. The major limiting factor in our country is

lack of adequate resources to set up enough labs all over the

country. It would also raise a question of affordability by

> the patients for pharmacogenetic testing. This concern has been

validated with the reduction in total health care expenses that the

patient has to face in event of therapeutic failures or adverse drug

reactions. There are enough agencies to fund research projects on

genomics, which are remaining unutilized. These depot of resources

like DBT, DST, ICMR, CEFIPRA etc are to be utilized by various

institutions all over the country and set up pharmacogenetic labs

with personnel. This has a long way to go, with the current rate of

progress in research.

>

> Dr.Surendiran

> JIPMER

>

>

>

> Chat on a cool, new interface. No download required. Click

here.

>

>

>

>

>

>

>

>

>

>

> 5, 50, 500, 5000 - Store N number of mails in your inbox. Click

here.

>

>

>

>

>

>

>

>

>

>

> <!--

>

> #ygrp-mkp{

> border:1px solid #d8d8d8;font-family:Arial;margin:14px

0px;padding:0px 14px;}

> #ygrp-mkp hr{

> border:1px solid #d8d8d8;}

> #ygrp-mkp #hd{

> color:#628c2a;font-size:85%;font-weight:bold;line-

height:122%;margin:10px 0px;}

> #ygrp-mkp #ads{

> margin-bottom:10px;}

> #ygrp-mkp .ad{

> padding:0 0;}

> #ygrp-mkp .ad a{

> color:#0000ff;text-decoration:none;}

> -->

>

>

>

> <!--

>

> #ygrp-sponsor #ygrp-lc{

> font-family:Arial;}

> #ygrp-sponsor #ygrp-lc #hd{

> margin:10px 0px;font-weight:bold;font-size:78%;line-height:122%;}

> #ygrp-sponsor #ygrp-lc .ad{

> margin-bottom:10px;padding:0 0;}

> -->

>

>

>

> <!--

>

> #ygrp-mlmsg {font-size:13px;font-family:arial, helvetica, clean,

sans-serif;}

> #ygrp-mlmsg table {font-size:inherit;font:100%;}

> #ygrp-mlmsg select, input, textarea {font:99% arial, helvetica,

clean, sans-serif;}

> #ygrp-mlmsg pre, code {font:115% monospace;}

> #ygrp-mlmsg * {line-height:1.22em;}

> #ygrp-text{

> font-family:Georgia;

> }

> #ygrp-text p{

> margin:0 0 1em 0;}

> #ygrp-tpmsgs{

> font-family:Arial;

> clear:both;}

> #ygrp-vitnav{

> padding-top:10px;font-family:Verdana;font-size:77%;margin:0;}

> #ygrp-vitnav a{

> padding:0 1px;}

> #ygrp-actbar{

> clear:both;margin:25px 0;white-space:nowrap;color:#666;text-

align:right;}

> #ygrp-actbar .left{

> float:left;white-space:nowrap;}

> .bld{font-weight:bold;}

> #ygrp-grft{

> font-family:Verdana;font-size:77%;padding:15px 0;}

> #ygrp-ft{

> font-family:verdana;font-size:77%;border-top:1px solid #666;

> padding:5px 0;

> }

> #ygrp-mlmsg #logo{

> padding-bottom:10px;}

>

> #ygrp-vital{

> background-color:#e0ecee;margin-bottom:20px;padding:2px 0 8px 8px;}

> #ygrp-vital #vithd{

> font-size:77%;font-family:Verdana;font-weight:bold;color:#333;text-

transform:uppercase;}

> #ygrp-vital ul{

> padding:0;margin:2px 0;}

> #ygrp-vital ul li{

> list-style-type:none;clear:both;border:1px solid #e0ecee;

> }

> #ygrp-vital ul li .ct{

> font-weight:bold;color:#ff7900;float:right;width:2em;text-

align:right;padding-right:.5em;}

> #ygrp-vital ul li .cat{

> font-weight:bold;}

> #ygrp-vital a{

> text-decoration:none;}

>

> #ygrp-vital a:hover{

> text-decoration:underline;}

>

> #ygrp-sponsor #hd{

> color:#999;font-size:77%;}

> #ygrp-sponsor #ov{

> padding:6px 13px;background-color:#e0ecee;margin-bottom:20px;}

> #ygrp-sponsor #ov ul{

> padding:0 0 0 8px;margin:0;}

> #ygrp-sponsor #ov li{

> list-style-type:square;padding:6px 0;font-size:77%;}

> #ygrp-sponsor #ov li a{

> text-decoration:none;font-size:130%;}

> #ygrp-sponsor #nc{

> background-color:#eee;margin-bottom:20px;padding:0 8px;}

> #ygrp-sponsor .ad{

> padding:8px 0;}

> #ygrp-sponsor .ad #hd1{

> font-family:Arial;font-weight:bold;color:#628c2a;font-

size:100%;line-height:122%;}

> #ygrp-sponsor .ad a{

> text-decoration:none;}

> #ygrp-sponsor .ad a:hover{

> text-decoration:underline;}

> #ygrp-sponsor .ad p{

> margin:0;}

> o{font-size:0;}

> .MsoNormal{

> margin:0 0 0 0;}

> #ygrp-text tt{

> font-size:120%;}

> blockquote{margin:0 0 0 4px;}

> .replbq{margin:4;}

> -->

>

>

>

>

>

>

>

>

> Save all your chat conversations. Find them online at

http://in.messenger../webmessengerpromo.php

>